AstraZeneca scoops the double!
At the prestigious annual Scrip Awards in London, AstraZeneca won the Best Partnership Alliance 2013 for a record fourth consecutive year. The award recognises the innovative three-party alliance between AstraZeneca and Bristol-Myers Squibb, and Amylin in diabetes.
The AstraZeneca-Bristol Myers Squibb diabetes alliance is the first to offer products in the three newest and fastest growing classes of diabetes treatments. Scrip is one of the world’s leading pharmaceutical and biotech news organisations. The Best Partnership Alliance award recognises the importance of partnerships involving pharmaceutical and / or biotech companies in developing novel therapeutics.
The Scrip Awards have been running for nine years. To learn more about this achievement and AZ’s partnership news click here.
Find out what inspiring things we’ve been up to recently.
One day it may be the announcement of a breakthrough medicine. The next, about how we’re coming to the aid of an area stricken by a natural disaster. Whether it’s for patients, co-workers, stakeholders or communities, we’re always proud of the people who are making a difference in healthcare and the pharmaceutical industry.
You can read up-to-the-minute press releases and catch up on AstraZeneca News at our news site on the main AstraZeneca site.
Or click here to read our Twitter feed.
Pascal Soriot profiled in Veckans Affärer
In a recent Veckans Affärer interview, CEO of AstraZeneca, Pascal Soriot talked to Jill Bederoff about innovation and being focused, saying “We want to come up with innovative new medicines that make a difference. Innovation is always difficult, but in our industry it is particularly difficult because it is not about physics or engineering, it is about biology where there are great unknowns. To succeed, one must be very talented and extremely focused.” To read the full article in Swedish, please click here.
Last reviewed: November 28, 2013